Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : IMMD - ImmuDyne -- Ignore unavailable to you. Want to Upgrade?

To: Mel Fox who wrote (1185)	5/15/1998 11:05:00 AM
From: Catfish	Read Replies (1) \| Respond to of 1249

Friday May 15, 8:31 am Eastern Time Company Press Release ImmuDyne Inc. Announces Notice of Allowance for a New Patent HOUSTON--(BW HealthWire)--May 15, 1998--ImmuDyne Inc. (OTC BB:IMMD - news) announced that it received a Notice of Allowance from the U.S Patent Office for a new patent for the company's products. The new patent, authored by Dr. Leonid Ber, COO of ImmuDyne, has been assigned directly to the company and is expected to be issued within a short period of time. Management stated that this new patent will contribute significantly to the value of the intellectual property portfolio currently held by the company. Management stated that in addition to advancements in research and development, the company will continue to vigorously and aggressively enforce all court orders, as described in previous press releases, to ensure that all opposing parties follow those orders. Management further stated that the company will not lose focus and will not be denied in its mission of working to build its business and to strive to improve shareholder value. ''Safe Harbor'' Statement under the Private Securities Litigation Reform Act of 1995. The statements which are not facts contained in the release are forward-looking statements that involve risks and uncertainties, some of which are outside the company's control, and accordingly, actual results may differ materially. Factors that might cause such a difference include, but are not limited to, implementation of the company's strategies, the impact of competitive and industry developments, the results of research and development efforts by the company, product development by the company and customer acceptance of the company's products and services. ImmuDyne is a Texas-based company specializing in macrophage technology and immune systems stimulants for cosmetic, human nutritional and aquacultural use. The common stock of ImmuDyne is traded on the OTC Bulletin Board under the symbol IMMD. For investment information, contact the company at 713/783-7034. -------------------------------------------------------------------------------- Contact: ImmuDyne Inc., Houston 713/783-7034